ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 2776

Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis

Suzanne Kafaja1, Isela Valera2, Anagha Divekar3, Rajan Saggar4, Dinesh Khanna5, Daniel E. Furst6 and Ram R. Singh7, 1Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, 2Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 3Biolegend, Sa Diego, CA, 4Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5University of Michigan, Ann Arbor, MI, 6David Geffen School of Medicine at UCLA, Los Angeles, CA, 7Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Dendritic cells, fibrosis, Lung Disease, skin fibrosis and systemic sclerosis

Session Information

Date: Tuesday, November 7, 2017

Title: Innate Immunity and Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells and innate immune cells including dendritic cells (DC) in the development of fibrosis. DCs play a role in T-cell priming and differentiation also infiltrate the lung in response to bleomycin injection in animals. DCs also accumulate in lungs of patients with idiopathic pulmonary fibrosis and in skin of patients with systemic sclerosis (SSc) . However, the exact role of DCs in the pathogenesis of fibrotic diseases including SSc is unclear. We investigated the role of plasmacytoid dendritic cells (pDC) in the pathogenesis of systemic fibrosis using the bleomycin model and clinical samples from patients with systemic sclerosis (SSc).

Methods:

Female C57BL/6 mice were depleted of pDCs using anti-pDCA1 and were compared to mice depleted with isotype control IgG2b. clinical observation and analyses were carried of draining LN, spleen, lungs and skin including flow cytometry, pathology, collagen production and RT PCR array. In our work, we evaluated human data (HRCT and BAL) from SSc Imatinib trial. We also examined pDCs in Peripheral blood, skin and lung in controls as well as SSc patients.

Results:

pDCs were more profoundly increased than other immune cells in the lung and lung-draining lymph nodes, but not in the spleen, of bleomycin-injected mice compared to control animals. Depletion of pDCs improved the clinical score, lung histopathology score, skin thickness, and collagen content compared to control antibody-treated animals. B-cells, T-cells and natural killer T-cells were reduced in the lungs, but unaffected/increased in the spleen, of pDC-depleted mice as compared to controls. pDC-depleted mice also had a reduced expression of genes involved in chemotaxis, dendritic cell differentiation, inflammation, and fibrosis in the lungs as compared to controls. In humans, while pDCs were reduced in the peripheral blood of patients with SSc compared to healthy donors, their numbers were increased in the lung and skin of patients with SSc. The frequencies of pDCs in the bronchoalveolar lavage (BAL) correlated with SSc-lung disease scores and with IL-4+ and CD4+ T-cells in BAL.

Conclusion:

Taken together, our observations identify the increased trafficking to pDCs to the affected organs as a potential therapeutic target in fibrotic diseases.


Disclosure: S. Kafaja, None; I. Valera, None; A. Divekar, None; R. Saggar, None; D. Khanna, Actelion, Bayer, BoehringerIngelheim, Chemomab, Corbus, Covis, Cytori,Eicos, EMD Serono, Genentech/Roche, Gilead, GSK, Sanofi-Aventis,UCB Pharma, 5,NIH/NIAMS, NIH/NIAID,Bayer, BMS, Genentech/Roche, Pfizer, 2,Eicos, 4; D. E. Furst, Grant/Research Support: Amgen,BMS Novartis, Pfizer, Roche/Genentech,Corbus. Consultant:AbbVie, Amgen, BMS, Corbus, Cytori, , Novartis, Pfizer, Roche/Genentech,. Speakers Bureau(CME or non-promotional only): BMS, Abbvie NO stocks, royalties, direct fina, 2,see above, 5,see above, 8; R. R. Singh, None.

To cite this abstract in AMA style:

Kafaja S, Valera I, Divekar A, Saggar R, Khanna D, Furst DE, Singh RR. Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/plasmacytoid-dendritic-cells-in-systemic-fibrosis-pathogenic-role-in-bleomycin-induced-fibrosis-model-and-correlation-with-disease-in-patients-with-systemic-sclerosis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasmacytoid-dendritic-cells-in-systemic-fibrosis-pathogenic-role-in-bleomycin-induced-fibrosis-model-and-correlation-with-disease-in-patients-with-systemic-sclerosis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology